New study aims to ease life after ovarian and endometrial cancer
NCT ID NCT05731661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized post-cancer care plan for women who have finished treatment for ovarian or endometrial cancer. About 99 participants will receive a day of support care and a tailored plan to address their needs. The goal is to see if this approach improves their long-term quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- personalized post-cancer care plan
- What this could lead to
- If successful, this could lead to better long-term support and quality of life for women after pelvic cancer treatment.
- What could go wrong
- This is a small pilot study with no control group, so results may not be generalizable. It focuses on care coordination, not a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 99 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2023
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient \> 18 years old * Patient in complete remission after first-line treatment for endometrial or ovarian/fallopian tube/peritoneal cancer * Patient having completed her initial treatment; patients with maintenance treatments are eligible * Mastery of the French language * Patient with a telephone line * Patient affiliated to a social security scheme * Signature of informed consent before any specific procedure related to the study Exclusion Criteria: * Any associated medical or psychiatric conditions that could compromise the patient's ability to participate in the study * Patient with locoregional or metastatic recurrence * Patient deprived of liberty, under guardianship or curatorship * Simultaneous participation in a therapeutic clinical trial
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Advanced nurse practitioner are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Francois Baclesse
Caen, 14076, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can hormone pills replace chemo for aggressive endometrial cancer?
- Triple oral drug combo targets two stubborn gynecologic cancers
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- New PET tracer aims to light up hidden cancer targets